KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Other Non-Current Liabilities (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Other Non-Current Liabilities data on record, last reported at $19.1 million in Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities fell 62.41% year-over-year to $19.1 million; the TTM value through Dec 2025 reached $19.1 million, down 62.41%, while the annual FY2025 figure was $19.1 million, 62.41% down from the prior year.
  • Other Non-Current Liabilities reached $19.1 million in Q4 2025 per AMRX's latest filing, up from $8.1 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $87.5 million in Q4 2022 and bottomed at $549000.0 in Q1 2025.
  • Average Other Non-Current Liabilities over 5 years is $35.7 million, with a median of $29.0 million recorded in 2021.
  • Peak YoY movement for Other Non-Current Liabilities: crashed 86.54% in 2023, then surged 332.24% in 2024.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $38.9 million in 2021, then soared by 124.84% to $87.5 million in 2022, then plummeted by 86.54% to $11.8 million in 2023, then soared by 332.24% to $50.9 million in 2024, then crashed by 62.41% to $19.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $19.1 million in Q4 2025, $8.1 million in Q3 2025, and $15.6 million in Q2 2025.